Abstract 1339
Background
Esophageal squamous cell carcinoma (ESCC), a common gastrointestinal tumor, is listed as the sixth leading cause of cancer-related death worldwide, with high morbidity and mortality as its important characteristics. In recent years, despite advances in diagnosis and treatment of ESCC, the mortality rate of ESCC is still very high, with an average overall 5-year survival rate of about 10% ∼ 41%.As with many other solid tumors, development and progression of ESCC are also considered gene regulatory disorders caused by oncogene activation and inactivation accumulation and disorders of tumor suppressor genes (TSG). Therefore, screening and exploring the key gene proteins for the occurrence, development, treatment and clinical prognosis of ESCC is an important topic in the field of ESCC research at present.
Methods
Reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemical (IHC) staining were employed to determine IBSP expression at the mRNA and protein levels in clinical ESCC samples. Moreover, functional studies were adopted to study the tumor-promoter function of IBSP.
Results
IBSP up-regulation was found in 21 of 45 (46.7%) primary ESCC cells at mRNA level by transcription-polymerase chain reaction (RT-PCR). In addition, IHC staining further demonstrated that IBSP was up-regulated in ESCC cases and up-regulation of IBSP protein was significantly relevant to lymph node metastasis (P = 0.017), clinicopathologic stage (P = 0.001) and poor disease survival (P = 0.000) of ESCC patients. Moreover, functional studies illustrated that IBSP gene can promote the ability of proliferation and metastasis of ESCC cells. Furthermore, it was found that IBSP can regulate the EMT process by regulating MMP2 gene and N-cadherin, which promotes the metastasis of tumor cells.
Conclusions
the results of this study showed that IBSP up-regulation was often found in ESCC tumor specimens, indicating poor prognosis of ESCC patients. Moreover, it also demonstrated that IBSP could improve the ability of ESCC cell proliferation and tumor metastasis, which may be a valuable prognostic indicator in ESCC patients. Yet, the mechanism by which IBSP promotes tumorigenesis and development needs more researches.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
5595 - Is there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?
Presenter: Saadettin Kilickap
Session: Poster Display session 1
Resources:
Abstract
5840 - Crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase 2 clinical trial – Updated progression-free survival, overall survival and mechanisms of resistance
Presenter: Sebastian Michels
Session: Poster Display session 1
Resources:
Abstract
1905 - NTRK1-3 Genomic Fusions in Non-Small Cell Lung Cancer (NSCLC) Determined by Comprehensive Genomic Profiling
Presenter: Sai-Hong Ou
Session: Poster Display session 1
Resources:
Abstract
3016 - Preferential expression of the affected MET allele in lung carcinomas with heterozygous MET exon 14 skipping mutations: implications for clinical testing
Presenter: Evgeny Imyanitov
Session: Poster Display session 1
Resources:
Abstract
4120 - Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers
Presenter: Matthew G Krebs
Session: Poster Display session 1
Resources:
Abstract
3764 - Patients with metastatic non-small cell lung cancer and targetable molecular alterations in Germany. Treatment and first outcome data from the prospective German Registry Platform CRISP (AIO-TRK-0315)
Presenter: Frank Griesinger
Session: Poster Display session 1
Resources:
Abstract
4070 - Crizotinib vs Platinum-based Chemotherapy as First-line Treatment for Advanced Non-small Cell Lung Cancer with Different ROS1 Fusion Variants
Presenter: Haiyan Xu
Session: Poster Display session 1
Resources:
Abstract
5528 - Genomic and clinical characterization of Non-small cell lung cancer (NSCLC) patients harboring mutations in FGFR2 and FGFR3
Presenter: Matthias Scheffler
Session: Poster Display session 1
Resources:
Abstract
3779 - The expression of HER2-gene polymorphisms -1985G>T and P1170A C>G and their association with the risk of development of lung adenocarcinoma
Presenter: Ivan Aleric
Session: Poster Display session 1
Resources:
Abstract
3020 - Circulating tumor DNA (ctDNA) analysis depicts mechanisms of resistance and tumor response to BRAF inhibitors in BRAF-mutant non-small cell lung cancer (NSCLC)
Presenter: Sandra Ortiz - Cuaran
Session: Poster Display session 1
Resources:
Abstract